Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials

Antimicrob Agents Chemother. 2018 Dec 21;63(1):e01634-18. doi: 10.1128/AAC.01634-18. Print 2019 Jan.

Abstract

This pooled analysis evaluated the relationship of isavuconazole and voriconazole MICs of Aspergillus pathogens at baseline with all-cause mortality and clinical outcomes following treatment with either drug in the SECURE and VITAL trials. Isavuconazole and voriconazole may have had reduced efficacy against pathogens with drug MICs of ≥16 µg/ml, but there was no relationship with clinical outcomes in cases where the MIC was <16 µg/ml for either drug.

Keywords: MIC; clinical trial; isavuconazole; isavuconazonium sulfate; voriconazole.

Publication types

  • Clinical Trial, Phase III
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antifungal Agents / therapeutic use*
  • Aspergillosis / drug therapy*
  • Aspergillosis / microbiology
  • Aspergillosis / mortality
  • Aspergillus / drug effects*
  • Aspergillus / isolation & purification
  • Humans
  • Invasive Fungal Infections / drug therapy
  • Invasive Fungal Infections / microbiology
  • Microbial Sensitivity Tests
  • Nitriles / therapeutic use*
  • Pyridines / therapeutic use*
  • Triazoles / therapeutic use*
  • Voriconazole / therapeutic use*

Substances

  • Antifungal Agents
  • Nitriles
  • Pyridines
  • Triazoles
  • isavuconazole
  • Voriconazole